Ad
related to: upstream bio ipo
Search results
Results From The WOW.Com Content Network
Mercuria, in 2017, moved about 1.5 million barrels per day (240,000 m 3 /d), of crude and oil products and has upstream and downstream assets ranging from oil reserves in Argentina, Canada and the United States, to oil and products terminals in Europe and China, as well as substantial investment in the bio fuels plants in Germany and the Netherlands.
The company raised $300 million through private funding and a further $265 million through their IPO. On January 22, 2018, Juno Therapeutics was acquired by biotechnology company Celgene for $9 billion. [2] In November 2019, Bristol-Myers Squibb (BMS) announced that it has completed its acquisition of Celgene. [3]
Chevron's oil and gas exploration and production operations, which in the oil and gas industry are considered as "upstream" operations, are primarily in the US, Australia, Nigeria, Angola, Kazakhstan, and the Gulf of Mexico. As of December 31, 2018, the company's upstream business reported worldwide net production of 2.930 million oil ...
The IPO market, which has been in a lull in recent weeks, is likely to pick up steam just in time for a year-end push. Gaithersburg, Maryland-based Viela Bio, Inc., an AstraZeneca plc (NYSE: AZN ...
The upstream part of a bioprocess refers to the first step in which microbes/cells are grown, e.g. bacterial or mammalian cell lines (see cell culture), in bioreactors. Upstream processing involves all the steps related to inoculum development, media development, improvement of inoculum by genetic engineering process, optimization of growth ...
The proverbial biotech IPO window has been open for some time now, but it appears to have grown to the size of an airplane hangar door, allowing almost any biotech to go public at astonishingly ...
Although no clinical development took place, Axovant held its IPO in June 2015 and raised $315 million, [4] the largest biotech IPO ever, [9] based on new phase IIB trials that were more promising. [10] The lock-up period against reselling stock was reduced to an unusually short 90 days for hedge funds that showed interest in the IPO. [11]
CanSino Biologics was founded in 2009 in Tianjin by Yu Xuefeng, Zhu Tao, Qiu Dongxu and Helen Mao Huihua. [1]In July 2018, it filed an application to list on the Hong Kong Stock Exchange. [1]
Ad
related to: upstream bio ipo